About: Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Creator	Caliceti, Paolo Garofalo, Mariangela Kuryk, Lukasz Pancer, Katarzyna Salmaso, Stefano Staniszewska, Monika Wieczorek, Magdalena
Source	Medline; PMC
abstract	The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency. The serious outbreak position is affecting people worldwide and requires rapid measures to be taken by healthcare systems and governments. Vaccinations represent the most effective strategy to prevent the epidemic of the virus and to further reduce morbidity and mortality with long-lasting effects. Nevertheless, currently there are no licensed vaccines for the novel coronaviruses. Researchers and clinicians from all over the world are advancing the development of a vaccine against novel human SARS-CoV-2 using various approaches. Herein, we aim to present and discuss the progress and prospects in the field of vaccine research towards SARS-CoV-2 using adenovirus (AdV) replication deficient-based strategies, with a comprehension that may support research and combat this recent world health emergency.
has issue date	2020-06-10(xsd:dateTime)
bibo:doi	10.3390/vaccines8020293
bibo:pmid	32531955
has license	cc-by
sha1sum (hex)	4e140f0b78a7f451190043e3b2b5e1c948c9421d
schema:url	https://doi.org/10.3390/vaccines8020293
resource representing a document's title	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
has PubMed Central identifier	PMC7349996
has PubMed identifier	32531955
schema:publication	Vaccines (Basel)
resource representing a document's body	covid:4e140f0b78a7f451190043e3b2b5e1c948c9421d#body_text
is schema:about of	named entity 'SARS coronavirus 2' named entity 'current' named entity 'vaccine' named entity 'global health' named entity 'Vaccine' named entity 'APPEARANCE' named entity 'WORLD HEALTH' named entity 'PROGRESS' named entity 'MEASURES' named entity 'RECENT' named entity 'DEFICIENT' covid:arg/4e140f0b78a7f451190043e3b2b5e1c948c9421d named entity 'virus' named entity 'human' named entity 'Researchers' named entity 'emergency' named entity 'SARS-CoV-2' named entity 'epidemic' named entity 'vaccines' named entity 'world health emergency' named entity 'healthcare systems' named entity 'vaccine' named entity 'DNA-based vaccine' named entity 'protein' named entity 'infectious diseases' named entity 'cytotoxic T-cells' named entity 'SARS-CoV-2' named entity 'vaccination' named entity 'SARS' named entity 'neutralizing antibodies' named entity 'acute kidney injury' named entity 'infection' named entity 'NGDC' named entity 'vaccine' named entity 'vaccine' named entity 'antigen' named entity 'recombinant' named entity 'Hubei Province, China' named entity 'April 2020' named entity 'SARS-CoV-2' named entity 'adenovirus' named entity 'antigen' named entity 'COVID' named entity 'polypeptides' named entity 'lipid' named entity 'S protein' named entity 'smallpox vaccine' named entity 'vaccine' named entity 'neutralizing antibodies' named entity 'SARS-CoV' named entity 'exogenous' named entity 'vaccine' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'glycoprotein' named entity 'vaccine' named entity 'adenovirus' named entity 'SARS-CoV-2' named entity 'humoral' named entity 'adenoviral' named entity 'adenoviruses' named entity 'angiotensin-converting enzyme 2' named entity 'animal models' named entity 'exogenous' named entity 'Adenovirus' named entity 'humoral' named entity 'genetically engineered' named entity 'nucleocapsid' named entity 'Wuhan' named entity 'transgenes' named entity 'viruses' named entity 'strong immune' named entity 'AAV' named entity 'lentivirus' named entity 'proinflammatory cytokines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software